Related Experiment Video
Updated: Jul 15, 2025
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Targeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer
Myeongjin Jeon1, Sungpyo Hong2, Hyoungmin Cho1
1Research Center, Samjin Pharm. Co., Ltd., Seoul 07794, Republic of Korea.
Abstract:
Triple-negative breast cancer (TNBC) presents significant challenges due to its aggressive nature and limited treatment options. Focal adhesion kinase (FAK) has emerged as a critical factor promoting tumor growth and metastasis in TNBC. Despite encouraging results from preclinical and early clinical trials with various FAK inhibitors, none have yet achieved clinical success in TNBC treatment. This study investigates the therapeutic potential of a novel dual inhibitor of FAK and PYK2, named SJP1602, for TNBC. In vitro experiments demonstrate that SJP1602 effectively inhibits FAK and PYK2 activities, showing potent effects on both kinases. SJP1602 shows concentration-dependent inhibition of cell growth, migration, invasion, and 3D spheroid formation in TNBC cell lines, surpassing the efficacy of other FAK inhibitors. Pharmacokinetic studies in rats indicate favorable bioavailability and sustained plasma concentrations of SJP1602, supporting its potential as a therapeutic agent. Furthermore, in TNBC xenograft models, SJP1602 exhibits significant dose-dependent inhibition of tumor growth. These promising results emphasize the potential of SJP1602 as a potent dual inhibitor of FAK and PYK2, deserving further investigation in clinical trials for TNBC treatment.
Insights
A new drug, SJP1602, shows promise for treating triple-negative breast cancer (TNBC). This dual inhibitor of focal adhesion kinase (FAK) and PYK2 effectively reduced tumor growth and spread in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is aggressive with limited therapeutic options.
- Focal adhesion kinase (FAK) plays a key role in TNBC growth and metastasis.
- Existing FAK inhibitors have not yet succeeded clinically for TNBC.
Purpose of the Study:
- To investigate the therapeutic potential of SJP1602, a novel dual inhibitor of FAK and PYK2, for TNBC.
- To evaluate the in vitro and in vivo efficacy of SJP1602 in TNBC models.
Main Methods:
- In vitro assays assessing FAK/PYK2 inhibition, cell growth, migration, invasion, and 3D spheroid formation.
- Pharmacokinetic studies in rats.
- In vivo efficacy studies using TNBC xenograft models.
Main Results:
- SJP1602 potently inhibited FAK and PYK2 activity in vitro.
- SJP1602 demonstrated concentration-dependent inhibition of TNBC cell proliferation, migration, invasion, and spheroid formation.
- SJP1602 exhibited favorable pharmacokinetics and significant dose-dependent tumor growth inhibition in vivo.
- SJP1602 outperformed other FAK inhibitors in preclinical TNBC models.
Conclusions:
- SJP1602 is a potent dual inhibitor of FAK and PYK2 with significant preclinical efficacy against TNBC.
- SJP1602 warrants further clinical investigation for the treatment of triple-negative breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22PI3K/mTOR/AKT Signaling Pathway